Pharmaceutical companies must monitor adverse drug reactions (ADRs) from tens of thousands of sources—FAERS spontaneous reports, PubMed clinical articles, social media posts. Manual processing takes up to 90 minutes per report, yet serious cases must be submitted to the FDA within 15 days. Our AI pharmacovigilance automation accelerates this process 10-fold, automatically generate CIOMS reports, and cut operational costs by 60–80% (saving up to $500,000 annually for a mid-size pharma). Full development starting from $50,000. Our system supports CIOMS auto-filling for regulatory submission.
What core problems does the AI pharmacovigilance solve?
First, data volume. FAERS contains over 10 million reports, with thousands added daily. Manual signal detection is impossible. Second, unstructured data. Reports contain typos, abbreviations, and informal language (especially from social media). Third, compliance timelines. For serious unexpected ADRs, deadlines are tight. Our drug safety monitoring system pipeline reduces processing time from 45–90 minutes to 5–10 minutes with verification. Our NLP for adverse drug reactions capability handles diverse text formats.
Safety signal extraction methods
We use fine-tuned BioBERT for NLP tasks: drug name recognition, MedDRA coding, and causality assessment. MedDRA coding accuracy reaches F1 0.82–0.88. For social media, we apply classifiers to distinguish ADR reports from mentions without reaction. The pipeline includes negation detection (e.g., "patient did not experience nausea") and attribute attachment to the drug. This is our core adverse reaction extraction capability.
ML signal detection vs. traditional methods
Traditional disproportionality methods (PRR, ROR, BCPNN) do not account for confounding factors or temporal trends. Our ML signal detection models based on sparse matrices and neural networks detect signals 3 times faster. For example, acetaminophen hepatotoxicity would have been detected 18 months earlier with ML analysis. We also apply gradient boosting for signal prioritization by criticality. Our FAERS analysis pipeline integrates with EudraVigilance monitoring for cross-database signal validation.
What is included in the development package?
Our development package includes full project documentation (system architecture, model cards, API specs), access to trained models and source code, team training sessions, and post-deployment support for 3 months. We also provide MLOps pipeline setup and integration with your existing systems.
How does the development process work?
In practice, the process unfolds as follows: first, we analyze data sources and regulations (2–4 weeks), then design the NLP pipeline architecture (3–6 weeks), implement ADR extraction and signal detection modules (8–16 weeks), validate with A/B testing (4–6 weeks), and finally deploy on the client's infrastructure (2–4 weeks).
| Stage | Content | Duration |
|---|---|---|
| Analytics | Audit of data sources, regulations, integration points | 2–4 weeks |
| Design | NLP pipeline architecture, ML models, CI/CD MLOps | 3–6 weeks |
| Implementation | Development of modules: ADR extraction, signal detection, E2B(R3) generation | 8–16 weeks |
| Testing | Validation on historical data, A/B testing with manual review | 4–6 weeks |
| Deployment | Deployment on company infrastructure, integration with FAERS/EudraVigilance | 2–4 weeks |
Full development takes 4 to 8 months. Pricing starts at $50,000, with potential annual savings of up to $500,000.
Signal detection methods comparison
| Parameter | Statistical methods (PRR/ROR) | ML methods (gradient boosting, neural networks) |
|---|---|---|
| Time to signal detection | 6–12 months | 1–3 months (3x faster) |
| Confounding factor handling | Absent | Built into model |
| Adaptation to new data | Requires recalculation | Incremental learning |
| F1-score for MedDRA | 0.70–0.75 | 0.82–0.88 |
We also integrate MLOps practices: model versioning via MLflow, A/B tests on historical data, data drift monitoring. This ensures production stability.
Case study
For one client, we implemented a literature monitoring system. PubMed publishes thousands of articles daily. Manual screening took 2 hours per day. Our pipeline automatically downloads articles by keywords (drug + ADR), classifies relevance (filtering 90% irrelevant ones), and creates an expert queue. Analysis time dropped from 2 hours to 10 minutes (12x improvement). The system also drafts PSUR reports by aggregating all ADRs for the period. We used DistilBERT fine-tuned on a clinical annotation corpus, achieving F1 0.85 on relevance classification. Our system is 10 times more efficient than manual report processing.
Typical pitfalls in pharmacovigilance AI implementation
- Neglecting negation handling: A simple keyword search may flag "no adverse events" as an ADR. Our pipeline explicitly models negation scope.
- Ignoring temporal decay: Historical signals may not be relevant today. We incorporate time weighting in signal detection.
- Overlooking data privacy: Social media data requires anonymization. We implement de-identification before processing.
- Insufficient validation: Models must be validated on real-world data from the specific therapeutic area. We perform A/B testing against manual expert review.
Results and guarantees
With over 10+ years of experience in pharmaceutical AI and 50+ projects completed, we guarantee transparency: you receive model cards, pipeline documentation, and team training. Our engineers are certified in AWS and Google Cloud, with 5+ years of MLOps experience in pharma. We are a reliable partner with 5 years on the market. Request a consultation for a free project evaluation.